EZH2 and cancer: As the catalytic core component, Enhancer of Zeste Homolog 2 (EZH2) has been extensively analyzed, particularly because dysregulation of EZH2 is strongly oncogenic and has been observed in various cancers, making this protein an interesting therapeutic target [4].